Fulltext present in this item

Thumbnail
Fulltext: 51584.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.
Author(s): Allen, N.E.; Key, T.J.; Appleby, P.N.; Travis, R.C.; Roddam, A.W.; Rinaldi, S.; Egevad, L.; Rohrmann, S.; Linseisen, J.; Pischon, T.; Boeing, H.; Johnsen, N.F.; Tjonneland, A.; Gronbaek, H.; Overvad, K.; Kiemeney, L.A.L.M. ; Bueno-De-Mesquita, H.B.; Bingham, S.; Khaw, K.T.; Tumino, R.; Berrino, F.; Mattiello, A.; Sacerdote, C.; Palli, D.; Quiros, J.R.; Ardanaz, E.; Navarro, C; Larrañaga, N.; Gonzalez, C.; Sanchez, M.J.; Trichopoulou, A.; Travezea, C.; Trichopoulos, D.; Jenab, M.; Ferrari, P.; Riboli, E.; Kaaks, R.
Publication year: 2007
Source: Cancer Epidemiology, Biomarkers & Prevention, vol. 16, iss. 6, (2007), pp. 1121-1127
ISSN: 1055-9965
DOI: https://doi.org/10.1158/1055-9965.EPI-06-1062
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/51584   http://hdl.handle.net/2066/51584

Display more details
Subject: NCEBP 1: Molecular epidemiology
ONCOL 1: Hereditary cancer and cancer-related syndromes
ONCOL 3: Translational research
ONCOL 5: Aetiology, screening and detection
UMCN 1.1: Functional Imaging
UMCN 1.5: Interventional oncology
Organization: Urology
Health Evidence
Former Organization: Epidemiology, Biostatistics & HTA
Journal title:
Cancer Epidemiology, Biomarkers & Prevention
Volume: vol. 16
Issue: iss. 6
Page start: p. 1121
Page end: p. 1127
Abstract:
BACKGROUND: Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer. METHODS: We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression. RESULTS: The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; Ptrend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; Ptrend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; Ptrend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; Ptrend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-I concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; Ptrend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; Ptrend = 0.11) for IGF-I adjusted for IGFBP-3. CONCLUSIONS: In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed.

This item appears in the following Collection(s)

Browse

Statistics